FCHSD2 Inhibitors
Chemical inhibitors of FCHSD2 target various signaling pathways and kinases to achieve functional inhibition. Staurosporine and Genistein are broad-spectrum kinase inhibitors, with Staurosporine being particularly potent. These inhibitors can prevent the activation of FCHSD2 by inhibiting upstream kinases that would normally phosphorylate and activate FCHSD2, leading to a decrease in its activity. Similarly, LY294002 and Wortmannin specifically inhibit PI3K, a kinase that plays a central role in multiple signaling pathways. The inhibition of PI3K results in reduced production of PIP3, a critical second messenger involved in the activation of downstream proteins, which may include FCHSD2. Reduced PIP3 levels consequently prevent the activation of FCHSD2, leading to its functional inhibition. PP2 and Dasatinib, by inhibiting Src family kinases, also prevent the phosphorylation of FCHSD2, thus inhibiting its function. These chemicals ensure that the protein kinase activity necessary for FCHSD2 to function is blocked.
On the other hand, U0126 and PD98059 target the MAPK/ERK pathway by inhibiting MEK, which is upstream of ERK. The inhibition of this pathway prevents the necessary phosphorylation events that FCHSD2 may rely on for its activity. SB203580's inhibition of p38 MAP kinase and SP600125's inhibition of JNK both block the MAPK pathway at different points, but with a common consequence of preventing the activation of FCHSD2. Y-27632, as a ROCK inhibitor, disrupts cytoskeleton dynamics and signaling pathways that FCHSD2 could be involved in, therefore, its inhibition can lead to the reduced activity of FCHSD2. Lastly, Gö6976 inhibits PKC, which is involved in various cellular processes including those that could interact with FCHSD2. By inhibiting PKC, Gö6976 can interfere with the signaling pathways and cellular mechanisms necessary for FCHSD2's functional activity, resulting in its inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. FCHSD2 is involved in signal transduction processes mediated by kinases. Staurosporine inhibits multiple kinases that could be upstream regulators or direct activators of FCHSD2, resulting in the functional inhibition of FCHSD2 by preventing its phosphorylation or activation. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting tyrosine kinases, it can prevent the phosphorylation of FCHSD2, which may rely on such post-translational modifications for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. PI3K is part of signaling pathways that can regulate the activity of many proteins, including FCHSD2. Inhibition of PI3K can lead to a decrease in PIP3 levels, which in turn can prevent the activation of downstream proteins that may interact with or activate FCHSD2, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. Similar to LY294002, it leads to reduced PIP3 levels and can inhibit the functional activity of proteins regulated by the PI3K pathway, possibly including FCHSD2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases can phosphorylate and regulate various proteins involved in signaling pathways. Inhibiting Src kinases can prevent the phosphorylation and activation of FCHSD2, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Bcr-Abl and Src family kinase inhibitor. It can inhibit the kinase activity that might contribute to the activation or regulation of FCHSD2, thus inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is another MEK inhibitor that functions similarly to U0126 in inhibiting the MAPK/ERK pathway. The inhibition of this pathway can result in the functional inhibition of FCHSD2 due to a lack of activation signals. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. The p38 MAP kinase pathway is involved in stress responses and may regulate proteins including FCHSD2. Inhibition of p38 MAP kinase can thus result in the functional inhibition of FCHSD2 by preventing its stress-induced activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. By inhibiting JNK, SP600125 can prevent the downstream signaling events that could involve the regulation of FCHSD2, leading to its functional inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. Rho-associated, coiled-coil containing protein kinase (ROCK) is part of pathways that regulate cytoskeleton dynamics and could intersect with the functional activity of FCHSD2. Inhibition of ROCK can thus potentially inhibit the functional activity of FCHSD2 by altering the cytoskeletal dynamics and associated signaling pathways that FCHSD2 may rely on. | ||||||